1-Acetyl-4-(5-chlor-<1H>-indol-3-yl)-piperidin | 65347-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-Acetyl-4-(5-chlor-<1H>-indol-3-yl)-piperidin
• 英文别名: 1-acetyl-4-(5-chloro-[1H]-indol-3-yl)-piperidine；3-(1-acetyl-4-piperidyl)-5-chloro-1H-indole；1-acetyl-4-(5-chloro-indol-3-yl)-piperidine；1-[4-(5-chloro-1H-indol-3-yl)piperidin-1-yl]ethanone
• CAS: 65347-60-6
• 化学式: C₁₅H₁₇ClN₂O
• 分子量: 276.766
• InChiKey: YEPHYFKJTNLKOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Acetyl-4-(5-chlor-<1H>-indol-3-yl)-piperidin 在 氢氧化钾 作用下， 以 丙醇 、 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 为溶剂， 生成 4-(5-chloro-[1H]-indol-3-yl)-piperidine
  参考文献：
  名称：

  Novel 1,4-benzodioxanes

  摘要：

  1,4-苯并二氧杂环己烷类化合物的化学式为##STR1##其中R'选自氢、1至5个碳原子的烷氧基、氯、溴和氟的群组，R.sub.1和R.sub.2分别选自氢和1至5个碳原子的烷基，Y和Z为氢或共同形成双键，以其外消旋混合物或光学活性异构体的形式，以及具有降压活性的无毒、药学上可接受的酸盐和其制备的新方法和新中间体。

  公开号：

  US04100291A1
• 作为产物：
  描述：

  1-Acetyl-4-(5-chlor-<1H>-indol-3-yl)-1,4-dihydropyridin 生成 1-Acetyl-4-(5-chlor-<1H>-indol-3-yl)-piperidin
  参考文献：
  名称：

  DUMONT, C.;GUILLAUME, J.;NEDELEC, L.

  摘要：

  DOI：

文献信息

• Treating psychic disorders with piperidyl-indoles
  申请人：Roussel Uclaf

  公开号：US04196209A1

  公开（公告）日：1980-04-01

  Novel piperidyl-indoles of the formula ##STR1## wherein X is selected from the group consisting of fluorine, chlorine and bromine when Y and Z are hydrogen or together form a double bond and X is selected from the group consisting of hydrogen and alkoxy of 1 to 3 carbon atoms when Y and Z form a double bond and their non-toxic, pharmaceutically acceptable acid addition salts having antidepressant, antiemetic and antiparkinsonian activity and their preparations and novel intermediates therefore.

  该专利描述了一种新型哌啶基吲哚类化合物，其化学式为##STR1##其中，当Y和Z为氢或结合形成双键时，X选自氟、氯和溴的群体中；当Y和Z形成双键时，X选自1至3个碳原子的烷氧基和氢的群体中。该化合物及其无毒、药学上可接受的酸盐具有抗抑郁、抗恶心和抗帕金森症活性，以及其制剂和新型中间体。
• DUMONT, C.;GUILLAUME, J.;NEDELEC, L.
  作者：DUMONT, C.、GUILLAUME, J.、NEDELEC, L.

  DOI：——

  日期：——
• TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE
  申请人：Iomet Pharma Ltd.

  公开号：EP3082802B1

  公开（公告）日：2020-02-26
• Pharmaceutical Compound
  申请人：IOMET PHARMA LTD

  公开号：US20160367564A1

  公开（公告）日：2016-12-22

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X 2 , X 4 , X 10 , and X 11 may be the same or different and each is independently selected from C and N; X 1 , X 3 , X 5 , X 6 , X 7 , X 8 , and X 9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X 4 with the carbon atoms either side of X 2 are single bonds, and are only present when X 2 is absent, X 3 is absent and X 4 is C, and when these bonds are present the ring carbons on each side of X 2 are not directly bonded to each other; each R 1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 1 groups present is such that the valency of X 1 is maintained; each R 12 , R 13 , R 13′ , R 14 , R 15 and R 15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R 16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R 16 groups present is such that the valency of X 2 is maintained; each R 17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R 17 groups present is such that the valency of X 3 is maintained; each R 2 , R 3 , R 4 , and R 5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 6 , X 7 , X 8 , and X 9 are maintained; each R 7 , R 8 and R 9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X 10 , X 11 , and X 5 are maintained; and R 6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C 1 -C 6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.
• US4100291A
  申请人：——

  公开号：US4100291A

  公开（公告）日：1978-07-11